Keywords: Eisai, Halaven, UK, NICE, Breast cancer, Price discount

Eisai breast cancer drug still viewed as not cost effective by NICE

Article | 03 April 2012

Print This

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence (NICE) has issued new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in